Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1860657
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Allarity Therapeutics filed an 8-K on 9/24 for a 9/22 event. Check for updates.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on September 24, 2025, reporting an event on September 22, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company is incorporated in Delaware and its principal executive offices are located at 123 E Tarpon Ave, Tarpon Springs, FL 34689.
Why It Matters
This 8-K filing signals a material event or update from Allarity Therapeutics, Inc. that investors should be aware of, potentially impacting its stock.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for reporting events and exhibits, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- September 22, 2025 (date) — Earliest event reported
- September 24, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 123 E Tarpon Ave, Tarpon Springs, FL 34689 (address) — Principal executive offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates 'Other Events' as a reason for the report, but the specific event is not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on September 22, 2025.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive offices are located at 123 E Tarpon Ave, Tarpon Springs, FL 34689.
In which state is Allarity Therapeutics, Inc. incorporated?
Allarity Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Allarity Therapeutics, Inc.?
The SEC file number is 001-41160.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-09-24 07:58:49
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0258492-8k_allarity.htm (8-K) — 25KB
- ea025849201ex99-1_allarity.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-090872.txt ( ) — 226KB
- allr-20250922.xsd (EX-101.SCH) — 3KB
- allr-20250922_lab.xml (EX-101.LAB) — 33KB
- allr-20250922_pre.xml (EX-101.PRE) — 22KB
- ea0258492-8k_allarity_htm.xml (XML) — 4KB
01 Other Matters
Item 8.01 Other Matters. On September 22, 2025, Allarity Therapeutics, Inc. (the "Company") announced that announced that Dr. Jeremy Graff, the Company's President and Chief Development Officer, presented new and updated clinical data from the ongoing Phase 2 clinical trial in advanced ovarian cancer patients at the American Association for Cancer Research (AACR) 7 th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated September 22, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: September 24, 2025 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer 2